Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.37 |
| ▸ | PDE9A | O76083 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996694 | 1.00 | MAP4K4 (0.41) | MAP4K4KDM4EHTTPDE10APIK3C3 | |
| SCHEMBL13806028 | 0.92 | MAP4K4 (0.45) | MAP4K4KDM4EHTTPDE10APIK3C3 | |
| SCHEMBL21573257 | 0.92 | MAP4K4 (0.45) | MAP4K4KDM4EHTTPDE9AHSD11B1 | |
| SCHEMBL19905881 | 0.90 | MAP4K4 (0.44) | MAP4K4KDM4EPDE9AHSD11B1CHRM4 | |
| SCHEMBL19905886 | 0.90 | MAP4K4 (0.44) | MAP4K4KDM4EPDE9AHSD11B1CHRM4 | |
| SCHEMBL28059134 | 0.90 | MAP4K4 (0.44) | MAP4K4KDM4EPDE9AHSD11B1CHRM4 | |
| SCHEMBL25719734 | 0.87 | HTR2C (0.44) | MAP4K4CHRM4 | |
| SCHEMBL15345172 | 0.87 | PDE9A (0.43) | MAP4K4PDE10APDE9ACHRM4 | |
| SCHEMBL15345115 | 0.85 | MAP4K4 (0.42) | MAP4K4PIK3C3HSD11B1 | |
| SCHEMBL1740414 | 0.82 | HRH3 (0.38) | MAP4K4PDE9AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308229-A1 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197763-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | MAP4K4 573/4885KDM4E 796/4885HTT 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.